SAN DIEGO and MORGES, Switzerland, Sept. 26 /PRNewswire-FirstCall/ --
Biosite(R) Incorporated (Nasdaq: BSTE), a research-based provider of novel,
rapid medical diagnostics, today announced the opening of its new
headquarters for its European operations in Morges, Switzerland, near
Geneva. The new headquarters will manage the Company's sales, marketing and
customer support activities in Europe.
"Biosite's presence in the European market has grown dramatically since
we opened our first international office in France in 2003," said Gary
King, vice president, international operations. "The growth in our direct
sales operations in Europe requires a strategically located facility to
support our business strategy, particularly in the areas of marketing,
clinical and customer support."
The new mailing address is:
Biosite International Sarl
Rue des Vignerons, 1A
Morges 1110, Switzerland
Tel: +41 21 566 70 50
Fax: +41 21 802 09 33
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in more than 50 percent of
U.S. hospitals and in more than 60 international markets. Information on
Biosite can be found at http://www.biosite.com.
This press release contains forward-looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed
or implied by such statements. Examples of forward-looking statements are
financial targets and growth objectives and also include but are not
limited to statements that are preceded by, followed by, or that include
the words "will;" "believes;" "should;" "intend;" "anticipates;" "plans;"
"expects;" "estimates;" or similar statements. Forward-looking statements
in this press release include statements regarding Biosite's presence in
the European market and anticipated growth in sales, marketing, clinical
and customer support functions in Europe. Risks and uncertainties include
risks associated with Biosite's ability to obtain regulatory approvals and
complete other pre-market activities needed to launch new products as
currently planned, including the MPO test, a sepsis panel, a panel for
acute kidney injury and a Protein C test; Biosite's ability to effectively
promote and achieve market acceptance of any new products; the continued
growth of the BNP market generally, including the physician office market;
and other risks associated with changing market conditions and the effect
of competition from companies with greater capital and resources. Other
risks that should be considered are detailed in the Company's most recent
Annual Report on Form 10-K and other SEC filings. The Company disclaims,
however, any intent or obligation to update these forward-looking
statements. Copies of the Company's SEC filings are available from the
Investor Relations department or from the Company's website.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
http://www.prnewswire.com/comp/116737.html /
CONTACT:
Nicole Beckstrand, Manager, Public Relations
of Biosite Incorporated, +1-858-805-2803, nbeckstrand@biosite.com
|
